1. 152OEfficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib. (25th November 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J-F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 614TiPUCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis. (23rd October 2018) Authors: Mazard, T; Ghiringhelli, F; Mollevi, C; Assenat, E; Gavoille, C; Smith, D; Pezzella, V; Meddeb, R; Pastor, B; Ychou, M; Thierry, A R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 698PPhase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). (23rd October 2018) Authors: Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 783TiPCA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation. (23rd October 2018) Authors: Jimenez Exposito, M J; Akce, M; Montero Alvarez, J L; Assenat, E; Balart, L A; Baron, A D; Decaens, T; Heurgue-Berlot, A; Martin, A O; Paik, S W; Poulart, V; Sehbai, A S; Takemura, N; Yoon, J-H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-021Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). (2nd July 2019) Authors: Meyer, T; Finn, R; Kudo, M; Kang, Y; Yen, C; Galle, P; Llovet, J; Assenat, E; Brandi, G; Motomura, K; Okusaka, T; Hubner, R; Karwal, M; Baron, A; Ikeda, M; Liang, K; Wang, C; Widau, R; Schelman, W; Zhu, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P-099Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients. (2nd July 2019) Authors: Samalin, E; Mazard, T; Assenat, E; Rouyer, M; De la Fouchardière, C; Guimbaud, R; Smith, D; Portales, F; Ychou, M; Fiess, C; de Forges, H; Lopez-Crapez, E; Thézenas, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P-100Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. (20th June 2018) Authors: Cheng, A; Abou-Alfa, G; Ren, Z; Assenat, E; Cubillo, A; Pluntke, S; Rimassa, L; Ross, P; Wyrwicz, L; Hou, J; Li, C; Wu, J; Ducreux, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗